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ABSTRACT
Hypermethylation of CpG island (CGI) sequences
is a nearly universal somatic genome alteration
in cancer. Rapid and sensitive detection of DNA
hypermethylation would aid in cancer diagnosis
and risk stratification. We present a novel technique,
called COMPARE-MS, that can rapidly and quantitat-
ively detect CGI hypermethylation with high
sensitivity and specificity in hundreds of samples
simultaneously. To quantitate CGI hypermethylation,
COMPARE-MS uses real-time PCR of DNA that was
first digested by methylation-sensitive restriction
enzymes and then precipitated by methyl-binding
domain polypeptides immobilized on a magnetic
solid matrix. We show that COMPARE-MS could
detect five genome equivalents of methylated CGIs
in a 1000- to 10000-fold excess of unmethylated
DNA. COMPARE-MS was used to rapidly quantitate
hypermethylation at multiple CGIs in >155 prostate
tissues, including benign and malignant prostate
specimens, and prostate cell lines. This analysis
showed that GSTP1, MDR1 and PTGS2 CGI
hypermethylation as determined by COMPARE-MS
could differentiate between malignant and benign
prostate with sensitivities >95% and specificities
approaching 100%. This novel technology could
significantly improve our ability to detect CGI
hypermethylation.
INTRODUCTION
DNA methylation at the 5-position of cytosine in CpG dinuc-
leotides is an important aspect of physiological processes
including embryonic development, X chromosome inactiva-
tion, imprinting and transcriptional regulation (1–4). While
CpG dinucleotides are generally methylated throughout the
genome of normal somatic cells, CpG islands (CGIs), clusters
of CpG dinucleotides in gene regulatory regions, are usually
unmethylated (5). Aberrant hypermethylation of CGIs and
subsequent transcriptional repression is one of the earliest
and most common somatic genome alterations in multiple
human cancers (6,7). Some cancers even seem to exhibit a
so-called CpG island methylator phenotype (CIMP) (8). The
rapid and sensitive detection of DNA hypermethylation, there-
fore, would not only enhance our understanding of how DNA
methylation may contribute to carcinogenesis, but could aid in
early cancer diagnosis and risk stratiﬁcation (9,10).
Most of the current DNA methylation detection strategies
use sodium bisulﬁte to deaminate cytosine to uracil while
leaving 5-methylcytosine intact (11). Among these,
methylation-speciﬁc PCR (MSP) (12) uses PCR primers tar-
geting the bisulﬁte induced sequence changes to speciﬁcally
amplify either methylated or unmethylated alleles. Quantitat-
ive variations of this technique, such as MethyLight (13),
HeavyMethyl (14) and MethylQuant (15), employ
methylation-speciﬁc oligonucleotides in conjunction with
Taqman probes or SYBR Green based real-time PCR ampli-
ﬁcation to quantitate alleles with a speciﬁc pattern of methyla-
tion. These techniques are highly sensitive and speciﬁc for
detection of DNA methylation. However, all of the
bisulﬁte-based techniques are quite cumbersome, involving
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DNA and limit throughput. Additionally, PCR primer design
becomes difﬁcult due to the reduction in genome complexity
after bisulﬁte treatment, leading to an inability to interrogate
the methylation pattern at some or all CpG dinucleotides in a
genomic locus of interest.
Other DNA methylation detection assays use methylation-
sensitive restriction enzymes to digest unmethylated DNA
while leaving methylated DNA intact for detection by
Southern blot analysis (16–19), PCR (20,21) or real-time
PCR (22). The Southern blot strategy is not easily amenable
to high-throughput analysis and requires copious amounts of
high molecular weight DNA. Digestion followed by PCR is
sensitive,but islimitedto interrogating methylationonly atthe
enzyme recognition sites and is plagued by a propensity for
false-positives resulting from incomplete digestion.
Another strategy for in vitro methylation detection, ﬁrst
introduced in 1994 by Cross et al (23), uses column- or
bead-immobilized recombinant methylated-CpG binding
domain (MBD) proteins, particularly MECP2 (23–25) and
MBD2 (26), to enrich for methylated DNA fragments for
subsequent detection by Southern blot, PCR or microarray
hybridization. The MBD proteins are thought to bind specif-
ically to methylated chromosomal DNA in mammalian cells
(27), facilitating transcriptional silencing (28,29) by recruit-
ment of chromatin remodeling and transcriptional repression
complexes (30,31). A recent version of this strategy, called
MIRA (26), uses full-length MBD2 immobilized on magnetic
beads toenrich formethylated DNA with subsequent detection
of candidate methylated genes by PCR. Another assay, termed
MeDIP (32), uses bead-immobilized anti-5-methylcytosine
antibodies (a5mC-Abs), instead of MBD proteins, to enrich
for methylated DNA. However, the use of each these
techniques has been limited by one or more of the following:
a requirement for relatively large amounts of input genomic
DNA, a potential for false-positive results due to capture of
unmethylated DNA, incompatibility with high-throughput
platforms and lack of quantitative data.
In this study, we report the use of a novel technique, called
COMPARE-MS, that combines the use of methylation-
sensitive restriction enzymes with MBD assisted capture
and enrichment of methylated DNA followed by quantitative
PCR for sensitive, speciﬁc and rapid quantitation of
hypermethylated CGI sequences. We show that these two
strategies in combination complement each other, eliminating
many of the problems associated with using either technique
alone, while achieving sensitivities and speciﬁcities compar-
able with MSP, MethyLight and other bisulﬁte treatment-
based PCR techniques. Additionally, COMPARE-MS was
highly amenable to high-throughput, 96-well plate analysis,
and was used to rapidly determine the quantitative hyper-
methylation pattern at multiple CGIs for 155 prostate tissue
specimens, including malignant and benign tissues, and
multiple prostate cell lines.
MATERIALS AND METHODS
Cell culture, tissue samples and DNA isolation
Genomic DNA from LNCaP, PC3, LAPC4, C42B and
CWR22Rv1 prostate cancer cell lines, PrEC normal prostate
cells, prostate benign tissues from 13 brain-dead transplant
tissue donors with no evidence of prostate disease, primary
prostate cancer tissues from 130 men undergoing radical
prostatectomy and tumor-adjacent benign tissues from 12 of
these 130 men, were obtained as described previously (33).
DNA quantitation was carried out prior to restriction enzyme
digestion and MBD2-MBD capture and was performed by UV
absorbance on a standard spectrophotometer and veriﬁed by
real-time PCR of the Beta-globin gene to ensure that DNA was
of ample quality for reliable quantitative PCR ampliﬁcation
(22,34).
Cloning, expression and purification of MBD2-MBD
polypeptides
To produce recombinant His6-tagged MBD polypeptides from
the human MBD2 (MBD2-MBD), MBD2-MBD cDNA
sequence was ampliﬁed from clone MGC-45084 (American
Type Culture Collection), using PCR primers
50-GGATCCATGGAGAGCGGGAAGAGGATGGA and
50-GAATTCCATCTTTCCAGTTCTGAAGT containing
BamHI and EcoRI recognition sites. A modiﬁed pFastBac 1
baculovirus expression vector (Invitrogen), pFBC6H, was
generated by inserting the sequence CGCGGCAGCCAT-
CACCATCACCATCACTAA, which encodes a 6-histidine
tag, into pFastBac 1 between the EcoRI and XbaI sites. The
PCR ampliﬁed cDNA sequences were then introduced into
pFBC6H after linearization with BamHI and EcoRI. The
pFBC6H-MBD2-MBD expression constructs were used to
transform DH10Bac  Escherichia coli Competent Cells
(Invitrogen) to form MBD expression bacmids via site-
speciﬁc transposition. The expression bacmids were then
transfected into Sf9 insect cells for production of recombinant
MBD2-MBD polypeptide encoding baculovirus particles,
which were used to infect additional Sf9 cells (1 MOI,
48 h) to generate recombinant MBD2-MBD proteins contain-
ing a C-Terminal 6x histidine tag. Recovery of recombinant 6-
His-tagged MBD2-MBD polypeptides was accomplished by
methodssimilartothosedescribedpreviously(35).Brieﬂy,the
infected Sf9 cell pellets were resuspended in native binding
buffer containing 50 mM NaPO4, 0.5 M NaCl, 10 mM
imidazole and 1· Complete EDTA-free Protease Inhibitor
cocktail (Roche Diagnostics). Cells were lysed by two
freeze-thaw cycles and the DNA was sheared by passing
the sample through 20-gauge needles 4–6 times. The soluble
fraction was mixed with pre-washed Ni-NTA Superﬂow resin
(Qiagen) and incubated at 4 C for 2 h with rotation to allow
maximum binding. The supernatant, designated as ﬂow-
through, was removed after centrifugation for 1 min at
1000 r.p.m. (IEC HN-SII Centrifuge). The resin was washed
three times with 1· Native Wash Buffer containing 50 mM
NaPO4, 0.5 M NaCl, 35 mM imidazole and 1· Complete
EDTA-free Protease Inhibitor cocktail. The recombinant pro-
teins were then eluted from the resin with Native Elution
Buffer (50 mM NaPO4, 0.5 M NaCl, 250 mM imidazole
and protease inhibitor cocktail). The eluates were subjected
to buffer exchange using an Amicon Ultra-15 centrifugal ﬁlter
device (5000 MWCO, Millipore). The recombinant proteins
were stored in buffer containing 20 mM HEPES buffer, 0.1 M
KCl, 0.2 mM EDTA, 0.5 mM DTT, 20% glycerol and 1·
Complete EDTA-free Protease Inhibitor cocktail at  80 C
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MBD2-MBD polypeptide was determined by the BCA
assay (Pierce, Rockford, IL).
Fluorescence polarization analysis of MBD polypeptide
binding to oligonucleotide substrates
Aliquots containing 10 nM of annealed, ﬂuorescently labeled
hairpin oligonucleotides with the sequence 50-6FAM-
ATCGTCGTACGTTTTCGTACGACGAT-30 with no
methylated CpGs (unmethylated hairpin), two methylated
CpGs at the 2nd and 5th CpGs from the 50 end (one symmet-
rically methylated CpG hairpin), three methylated CpGs
toward the 30 end (three asymmetrically methylated CpG hair-
pin), four methylated CpGs at the 1st, 2nd, 5th and 6th CpGs
from the 50 end (two symmetrically methylated CpG hairpin)
or six methylated CpGs (three symmetrically methylated CpG
hairpin) were incubated with varying concentrations of recom-
binant MBD2-MBD in a 50 ml reaction volume containing 4%
glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50 mM
NaCl, 10 mM Tris–HCl (pH 7.4), 0.2% Tween-20 for 1 h at
room temperature with gentle shaking. Fluorescence polariza-
tion measurements were taken in triplicate using a Beckman
Coulter DTX 880 Multimode Detector as described previously
(35). Brieﬂy, ﬂuorescence anisotropies (r) were calculated as
r ¼ð Ik   I?Þ=ðIk þ 2I?Þ
where Ik represents the ﬂuorescence intensity parallel to the
incident light, I? represents the ﬂuorescence intensity perpen-
dicular to the incident light. In order to estimate the EC50,
which isdeﬁned astheeffectiveproteinconcentration required
for binding 50% of the hairpin oligonucleotides, r was plotted
against MBD2-MBD polypeptide concentration, and
curve-ﬁtted to a sigmoidal binding curve using Sigma Plot
8.0 (Systat Software, Richmond, CA).
COMPARE-MS assay and real-time PCR
An overview of the COMPARE-MS assay is shown in
Figure 1. DNA samples were digested at 37 C for 3 h with
15 U AluI (NEB, Beverly, MA) with or without 15 U of HpaII
Figure 1. COMPARE-MS overview and rationale. Genomic DNA is digested with AluI with or without the methylation-sensitive restriction enzyme HpaII. After
digestion, either the MBD2-MBD captured methylated DNA or all digested DNA are subjected to real-time PCR at a gene-specific locus. We hypothesized that
enrichmentofmethylatedDNAbymethylation-sensitiverestrictionenzymedigestionaloneorbyMBD2-MBDcaptureofmethylatedDNAalonemayresultinfalse
positivesassociatedwithincompletedigestionornonspecificcapture,respectively,whilethecombinationofthetwoapproaches(COMPARE-MS)wouldmaintain
sensitivity while minimizing false-positive results.
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were heat inactivated at 65 C for 30 min. Aliquots containing
2.5 ml of Protein G Magnetic Beads (NEB, Beverly, MA) were
gently shaken for 1 h at room temperature with 1 mgo f
PentaHis Antibody (Qiagen, Valencia, CA), 160 nM
MBD2-MBD-His6 and 200 ng of an unmethylated self-
ligated TOPO-TA plasmid (Invitrogen, Carlsbad, CA), in
97.5 ml of BW Buffer [4% glycerol, 1 mM MgCl2, 0.5 mM
EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM Tris–HCl (pH
7.4), 0.2% Tween-20 and 1· Complete EDTA-free Protease
Inhibitor cocktail]. Unbound antibody and MBD polypeptides
were removed by immobilizing beads on a Magnetight HT96
magnetic rack (Novagen, San Diego, CA) and removing the
supernatant. Restriction enzyme digested DNA samples were
diluted in 100 ml of BW buffer and then incubated with the
beads for 1 h at room temperature with gentle shaking. The
beads were then immobilized on the Magnetight HT96 rack
and washed ﬁve times with BW Buffer. After the ﬁnal wash,
20 ml of 1 mM Tris–HCl (pH 8.0) was added and the reaction
was heated to 95 C for 15 min to elute the DNA. The magnets
were again immobilized on the Magnetight HT96 rack and the
supernatant containing the released DNA was removed and
stored at  20 C until further use. These DNA samples were
then subjected to real-time PCR in 50 ml reaction volumes
containing 1· IQ SYBR Green Supermix (Biorad, Hercules,
CA), and 400 nM forward and reverse primers. Primer
sequences for assayed CGIs are shown in Table 1. PCRs
consisted of a 95 C denaturing step for 10 min, followed
by 45 cycles of 94 C for 30 s, 60 C for 30 s with real-time
detection and 72 C for 30 s. All assays were carried out in
duplicates or triplicates. All real-time PCR amplicons
contained at least one HpaII restriction enzyme site. M.SssI
(NEB) treated male WBC genomic DNA served as a positive
control for all CGIs while untreated male WBC genomic DNA
served as a negative control. The completion of the M.SssI
methyltransferase reaction was veriﬁed by showing that the
treated DNA could not be fragmented by HpaII restriction
enzyme and that all CpGs at the GSTP1 promoter CGI
were methylated by bisulﬁte genomic sequencing (36) (data
not shown). For prostate cell lines and tissues, methylation
levels were normalized to the signal generated by an equal
input amount of the positive control to generate a methylation
index (MI), which was displayed using a color scale in which
red indicates MI > 0.99 and white indicates MI ¼ 0. Because
a quantitative internal control could not be used for each
sample, it is important to note that accurate quantitation of
DNA in each sample prior to COMPARE-MS analysis is
crucial to the accuracy of COMPARE-MS. In this study,
DNA quantitation of all samples was performed prior to
restriction enzyme digestion and MBD2-MBD capture by
UV absorbance and by real-time PCR of the Beta-globin
gene. In the few samples in which there was a discrepancy
between the absorbance and real-time PCR derived quantities,
the real-time PCR quantity was used since this would be a
better estimate of ampliﬁable DNA. As a post-analysis quality
check, for specimens that had no detectable signals at all CGIs
tested by COMPARE-MS, real-time PCR ampliﬁcation of
LINE1 repetitive elements, which are methylated to a large
extent in human genomic DNA, using primers complementary
to the LINE1 promoter consensus sequence (GenBank
accession X58075), was performed to ensure that recovery
of methylated DNA was not compromised during
COMPARE-MS (data not shown).
Bisulfite genomic sequencing
An aliquot of 500 ng of genomic DNA was bisulﬁte converted
using the EZ DNA methylation kit (Zymo Research, Orange,
CA) and eluted in 10 ml of TE buffer, pH 7.4. Primers amp-
lifying GSTP1 CpG islands without bias to methylation pat-
terns were forward primer, 50-GTTGGTTTTATGTTGGGAG
TTTTGAGTTTT; reverse primer, 50-ATCCTCTTCCTAC-
TATCTATTTACTCCCTAA. PCR was carried out in 40 ml
reactions containing 1 ml of bisulﬁte converted DNA, 1·
Platinum Taq buffer (Invitrogen, Carlsbad, CA), 1.5 U
Platinum Taq (Invitrogen), 250 mM each dNTPs, 1.5 mM
Table 1. PCR primers used in COMPARE-MS assay
Gene symbol Forward primer Reverse primer
GSTP1 50-GGGACCCTCCAGAAGAGC 50-ACTCACTGGTGGCGAAGACT
PTGS2 (COX2) 50-GGAGAGGAAGCCAAGTGTCC 50-GGTTTCCGCCAGATGTCTTT
MDR1 (ABCB1) 50-GTGGGTGGGAGGAAGCAT 50-TCTCCAGCATCTCCACGAAG
ESR1 50-CTCGGGCTGTGCTCTTTTTC 50-CCAGATGCTTTGGTGTGGAG
DAPK1 50-CTTGCAGGGTCCCCATTG 50-GTCCGGCTGTCCTCCTCA
CDH1 50-CAGGTGAACCCTCAGCCAAT 50-CACAGGTGCTTTGCAGTTCC
LINE1 50-CGCAGAAGACGGGTGATTTC 50-CCGTCACCCCTTTCTTTGAC
Figure 2. Baculovirus-mediated expression of C-terminal His6-tagged human
MBD2-MBD in Sf9 insect cells and purification by Ni-NTA beads. Unbound
lysate, washes and eluted purified protein were run on an SDS–PAGE gel
and stained with Coomassie Blue R-250. The eluate contained the purified
 9.8 kDa MBD2-MBD- His6.
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forward primer and 400 nM reverse primer. Cycling condi-
tions were 95 C for 3 min, 35 cycles of 95 C for 30 s, 50 C for
30 s and 72 C for 30 s, followed by a 7 min extension step at
72 C. PCR products were gel puriﬁed after electrophoresis on
a 1% agarose gel, sub-cloned into pCR 2.1-TOPO  vector
(Invitrogen) and analyzed by dideoxy sequencing.
Statistical analysis
Receiver operator characteristic (ROC) curves were generated
using MedCalc (Mariakerke, Belgium) by plotting sensitivity
(%) versus 100-speciﬁcity (%) for varying MI thresholds. The
130 primary prostate cancer tissues were deﬁned as true
positives while the 13 benign prostate tissues from organ
donors were designated true negatives. These curves were
used to determine the MI threshold that yields the optimal
sensitivity and speciﬁcity. Area under the ROC curves
(AUC) and their 95% conﬁdence intervals were found. The
AUC represents the probability that a randomly chosen sample
from the true positives group will have an MI that is greater
than a randomly chosen sample from the true negatives
group. All error bars shown in this study represent SEM.
Figure 3. DeterminationofMBD2-MBDaffinityforsymmetricallymethylatedhairpinolignucleotideligands.(A–C) Fluorescenceanisotropymeasurementswere
plotted as a function of MBD2-MBD concentration in order to estimate the relative affinity of MBD2-MBD for fluorescently labeled hairpin oligonucleotides
containing three pairs (A), two pairs (B) and one pair (C) of symmetrically methylated CpG dinucleotides. The EC50, defined as the MBD2-MBD concentration
required to achieve half maximal binding of 10 nM hairpin oligonucleotides, is shown for each case, along with the corresponding SEM. Data shown represent
mean ± SEM for triplicate measurements.
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was performed with SigmaPlot 8.0.
RESULTS
Fluorescence anisotropy measurements for the
estimation of MBD2-MBD affinity for various
DNA templates
His6-tagged MBD of human MBD2 (MBD2-MBD) was
expressed in Sf9 insect cells using a baculoviral expression
system and puriﬁed using Ni-NTA Superﬂow beads (Qiagen,
Valencia, CA) (Figure 2). The afﬁnities of MBD2-MBD for
ﬂuorescently labeled hairpin oligonucleotides containing
various conﬁgurations of CpG methylation were then determ-
ined by ﬂuorescence polarization (Figure 3). The EC50 for
MBD2-MBD binding to hairpin oligonucleotides containing
two or three symmetrically methylated CpGs was 156 and
222 nM, respectively (Figure 3A and B). For hairpin oligo-
nucleotides with a single symmetrically methylated CpG
(Figure 3C) the EC50 ¼ 519 nM. In contrast, the MBD2-
MBD did not bind asymmetrically methylated and unmethyl-
ated hairpin oligonucleotides to any appreciable extent in the
concentration range tested suggesting that the EC50 >> 10 mM
for these ligands (data not shown). The high afﬁnity and spe-
ciﬁcity of MBD2-MBD for symmetrically methylated DNA
made it ideal for enrichment and capture of methylated DNA
from heterogeneous samples.
Dynamic range of detection of methylated GSTP1
CGIs by COMPARE-MS and each of its components
individually
We compared the abilities of digestion with a methylation-
sensitive restriction enzyme alone, MBD2-MBD capture of
methylated DNA alone, and the combination of the two
approaches in distinguishing between methylated and
unmethylated GSTP1 promoter CGIs (Figure 4). Genomic
DNA containing completely methylated GSTP1 promoter
CGIs was generated by treating WBC genomic DNA,
which is normally unmethylated at this CGI, with M.SssI
DNA methyltransferase. In an ideal methylation assay,
100% of the M.SssI-treated DNA would be detected while
the amount of falsely detected untreated WBC DNA would
diminish to zero. For this scenario, the dynamic range, deﬁned
as the amount of methylated alleles detected in the
M.SssI-treated DNA divided by the amount falsely detected
in the untreated WBC DNA, would approach inﬁnity.
HpaII restriction enzyme digestion followed by real-time
PCR with primers ﬂanking a single recognition site achieved a
dynamic range of  6- to 10-fold at all concentrations of input
DNA tested (Figure 4A). These data are in agreement with a
previous study showing adynamic range of 10-foldwhenthe
amplicon contains one HpaII recognition sequence (21).
MBD2-MBD capture of methylated DNA alone followed
by real-time PCR showed a maximum dynamic range of
 500- to 700-fold at high (4–100 ng) input DNA amounts
steadily decreasing to a minimum dynamic range of approx-
imately 3- to 10-fold at low (32 pg) input DNA amounts
(Figure 4B). At high concentrations of input DNA, a small
amount of untreated WBC DNA was detected above
background, but this was likely due to nonspeciﬁc binding
of the unmethylated DNA to the beads as opposed to speciﬁc
binding of unmethylated DNA to the MBD2-MBD, since the
same amount of background DNA capture occurred even in
the absence of MBD2-MBD (Figure 4C). When input DNA
was ﬁrst cut with HpaII, then precipitated with the MBD2-
MBD, and ﬁnally subjected to real-time PCR, the maximum
dynamic range was  5000- to 10000-fold with 20–100 ng
input DNA, decreasing to 10-fold at 32 pg (5–6 genomic
equivalents) input DNA (Figure 4D). Therefore, the combina-
tion of these techniques, termed COMPARE-MS, is superior
to either technique used alone. Furthermore, the ability to
detect hypermethylated GSTP1 CGIs was highly linear
(R
2 ¼ 0.982) over a 3125-fold range of input DNA. In
contrast, the signals from unmethylated DNA templates
were uniformly low and unrelated to input DNA amount
(R
2 ¼ 0.113), suggesting that these low signals were due to
the random noise in the assay, likely resulting from carrying
out high cycle numbers in real-time PCR.
In sum, the COMPARE-MS assay could allow reliable
quantitation of methylated CGIs even when only 0.03% or
1/3125 of input alleles are methylated. This sensitivity and
speciﬁcity could allow accurate detection of hypermethylated
cancer DNA in >1000-fold excess unmethylated normal DNA,
as would be found in heterogeneous DNA samples obtained
from non-dissected tissues, biopsy specimens and bodily
ﬂuids.
COMPARE-MS assay performance in simulated
heterogeneous samples
To test this potential more directly, we examined the
COMPARE-MS assay’s performance by using it to analyze
samples containing decreasing amounts (20 ng–32 pg) of
Figure 4. COMPARE-MS assay performance. (A and B) Plots showing the measured amount of methylated GSTP1 CGIs in M.SssI treated and untreated WBC
genomicDNAversustheamountofinputDNAafterenrichingformethylatedDNAbymethylation-sensitiverestrictionenzymesalone(A)orMBD2-MBDcapture
alone (B). (C) Plotof relativeenrichment of M.SssItreatedor untreatedWBCDNA withor withoutMBD2-MBD, anti-Hisantibodyand proteinGmagneticbeads.
The degree of capture of unmethylated DNA (untreated WBC DNA) in the presence of MBD2-MBD is less than or equal to the capture of DNA in the absence of
MBD2-MBD or anti-His antibody, showing that capture of unmethylated DNA during the DNA capture step of COMPARE-MS is almost completely due to low
amountsofnon-specificbindingtothe proteinGmagneticbeads,asopposedtolow-levelbindingoftheMBD2-MBDto unmethylatedDNA.(D)Plotsshowingthe
measured amount of methylated GSTP1 CGIs in M.SssI treated and untreated WBC genomic DNA versus the amount of input DNA after enriching for methylated
DNA by the combination of methylation-sensitive restriction enzyme digestion and MBD2-MBD capture (COMPARE-MS) followed by real-time PCR. When
20–100ngofinputDNAareused,COMPARE-MShasa>5000-folddynamicrange,whichis 500-foldhigherthanthatofmethylation-sensitiverestrictionenzyme
used alone and  5- to 10-fold higher than that of MBD2-MBD capture used alone. (E) Plot showing measured output methylated GSTP1 CGIs as determined by
COMPARE-MS when decreasing amounts of M.SssI-treated WBC DNA is diluted in 20 ng of untreated WBC genomic DNA. The dashed line is a reference
representing the mean COMPARE-MS output (0.0065 ± 0.0023 ng) when four identical replicates of 100 ng of untreated, unmixed WBC genomic DNA were
analyzed.COMPARE-MSperformanceinthisseriesofsimulatedheterogeneoussamples(E)ishighlylinearforalmostfourordersofmagnitudeandnearlyidentical
to that seen with homogeneously methylated samples (D), showing robust reproducibility and sensitivity. Data in (A–E) represent mean ± SEM for triplicate
measurements.
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(20 ng) of untreated WBC DNA (Figure 4E). These mixtures
are a simulation of heterogeneous samples. We used a ﬁxed
amountof20ngofuntreatedWBCgenomicDNA because this
represents a realistic amount we would want to input to actual
COMPARE-MS assays in order to conserve DNA specimens.
As anticipated by the dynamic range studies, the COMPARE-
MS assay had a linear quantitative response (R
2 ¼ 0.985) over
a broad dilution range spanning more than three orders of
magnitude. Furthermore, the assay performance in samples
diluted in excess unmethylated DNA was extremely similar
to the performance in samples containing pure methylated
DNA (Figure 4D and E). The COMPARE-MS assay could
reliably detect 32 pg (5–6 cells) of methylated DNA without
being overwhelmed by the 625-fold excess of unmethylated
genomic DNA. The same reliability in quantitation
was achieved when 32 pg of methylated DNA was diluted
in 100 ng ( 3125-fold) of excess unmethylated DNA (data not
shown), conﬁrming that accurate quantitation of GSTP1 CGI
hypermethylation could be achieved in mixtures containing
625- to 3125-fold excess contaminating unmethylated DNA.
CGI hypermethylation profile of prostate cancer cell
lines by COMPARE-MS
COMPARE-MS was used to assess the quantity of
hypermethylated CGI sequences at six cancer-related genes
in six prostate cancer cell lines and normal prostate epithelial
cells (PrECs) in primary culture (Figure 5). CGI sequences at
GSTP1, PTGS2 and MDR1 were found to be frequently and
prevalently methylated in multiple prostate cancer cell lines.
The ESR1 CGI was highly methylated in PC-3 cells, slightly
methylated in the DU-145 cells, but unmethylated in the other
cell lines. The CGI at DAPK1 was methylated to a small extent
in the PC-3 cell line. The CDH1 CGI was not methylated at
any of the prostate cancer cell lines. PrECs and WBCs were
not methylated at any of the CGIs tested. These experiments
demonstrate the general applicability of the COMPARE-MS
assay to CGIs at multiple genes (Figure 5A). With few
exceptions, the CGI methylation pattern in these cells determ-
ined by COMPARE-MS is extremely similar to the pattern
determined by MethyLight (Figure 5A and B) in a previous
study (33). Among the exceptions, the MethyLight study did
not detect any GSTP1 CGI hypermethylation in CWR22Rv1,
while COMPARE-MS detected a signiﬁcant amount of
methylated GSTP1 CGI alleles in this cell line. To test the
accuracy of the COMPARE-MS assay, we performed bisulﬁte
genomic sequencing of the GSTP1 CGI in DNA from
CWR22RV1, LNCaP and PrEC cells (Figure 5C). This
analysis showed that COMPARE-MS was accurate in predict-
ing a high degree of GSTP1 CGI hypermethylation in the
CWR22Rv1 cell line (MI ¼ 0.71). As seen by the bisulﬁte
sequencing data, the reason that MethyLight could not detect
any GSTP1 CGI hypermethylation in this sample is most
likely that many of the CpGs interrogated by the MethyLight
primers and probe were unmethylated in almost all of the
alleles. However, the ability of the COMPARE-MS assay
to correctly detect a high degree of hypermethylation at the
CWR22Rv1 was somewhat fortuitous since the HpaII site
interrogated by the COMPARE-MS assay was highly methyl-
ated in this cell line. For instance, when using a different set of
real-time PCR primers that ﬂank a single SmaI site at the 11th
CpG upstream of the  266 position of the GSTP1 promoter
(indicated in Figure 5C), the COMPARE-MS assay detects a
very low (MI ¼ 0.031), but greater than background degree of
hypermethylation (data not shown). Additionally, when WBC
DNA was partially methylated by M.HhaI and M.HpaII atnine
CpG sites (24% of all CpG sites) within the AluI fragment
interrogated by the COMPARE-MS assay, we detected just a
small, but greater than background, fraction of input alleles
(MI ¼ 0.036) compared with an equivalent input amount of
M.SssI methylated WBC DNA (data not shown). Therefore,
the dynamic range and diagnostic sensitivity of COMPARE-
MS would be limited if the CpGs interrogated by the
methylation-sensitive restriction enzyme is highly under-
methylated compared with the surrounding CpGs or if there
is a low density of methylation in the interrogated AluI
fragment. This limitation is not unlike that for MSP and
MethyLight when the CpGs interrogated by the
methylation-speciﬁc primers and probes are undermethylated
compared with the surrounding CpGs or when there is a low
density of methylation at the interrogated CpGs.
Detection of CGI hypermethylation by COMPARE-MS
in prostate cancer and benign prostate tissues
To test its performance on heterogeneous human tissues, the
COMPARE-MS assay was used to determine the extent of
methylation at the GSTP1, PTGS2, MDR1 and ESR1 CGIs
in benign prostate tissues from 13 transplant organ donors,
prostate cancer tissues from 130 men undergoing radical pro-
statectomy for treatment of localized prostate cancer and
tumor-adjacent benign prostate cancer tissues microdissected
from 12 of the 130 men undergoing radical prostatectomy
(Figure 6). We chose tissues such that a large subset of the
prostate cancer tissues analyzed in this study were analyzed by
MethyLight previously (33). Similar to the prostate cancer cell
lines, the CGIs at GSTP1 (99.2%), MDR1 (95.4%) and PTGS2
Figure 5. Validation of COMPARE-MS by analysis of hypermethylation at six gene-specific CGIs in multiple prostate cell lines. (A) Methylation index (MI),
definedastheratiooftheamountofmethylatedallelesinagivensampletotheamountofmethylatedallelesinthesameinputquantityofM.SssI-treatedWBCDNA,
as determined by COMPARE-MS, for six cancer-related genes (GSTP1, PTGS2, MDR1, ESR1, DAPK1 and CDH1) in 20 ng of genomic DNA from six prostate
cancer cell lines (LNCaP, C42B, PC-3, DU-145, LAPC-4 and CWR22Rv1), one primary culture model of non-malignant prostate epithelial cells (PrEC) and
untreatedWBCnegative control.(B) MI forthe same set ofCGIs andsamples asdeterminedby MethyLight in a previousstudy (33).With few exceptions, the CGI
hypermethylation pattern obtained from COMPARE-MS (A) is highly similar to those obtained from MethyLight (B). Asterisk denotes MI <0.2 but at least 3 SD
greaterthanthebackgroundlevelseenin10identicalreplicatesofWBCsamples.ThesedatademonstratetheapplicabilityofCOMPARE-MStomultiplegenesand
heterogeneous samples. (C) Bisulfite genomic sequencing of the GSTP1 CGI in PrEC, LNCaP and CWR22Rv1 cell lines. Bisulfite sequencing shows that
COMPARE-MS was accurate in identifying that the GSTP1 CGI in CWR22Rv1 cells is highly methylated, and demonstrates that MethyLight failed to detect
this because many of the CpG dinucleotides interrogated by the methylation specific primers and probe were mostly unmethylated. Both COMPARE-MS and
MethyLight were able to correctly identify that LNCaP and PrEC cells were homogeneously methylated and unmethylated, respectively. The indicated bisulfite
sequencing start and end positions are relative to the transcriptional start site.
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130 primary prostate cancer specimens and had, on average, a
high prevalence of methylated copies (mean and median
MI > 0.15). The ESR1 CGI was methylated in 47.7% of the
primary prostate cancers with a low, but above-threshold,
prevalence (mean and median MI < 0.03). In contrast, benign
prostate tissues from organ donors, who did not have evidence
of prostatic malignancies, had undetectable methylation at
these CGIs. Interestingly, many of the tumor-adjacent benign
tissues exhibited a low (mean and median MI < 0.02), but
above threshold, amount of CGI hypermethylation at the
GSTP1, MDR1 and PTGS2 genes (frequency of 58.3, 25
and50%,respectively).Amuchsmallerpercentageofthesetis-
sues had detectable CGI hypermethylation by the MethyLight
assay (33). ROC curves were used to analyze the optimal
sensitivity and speciﬁcity of GSTP1, MDR1 and PTGS2 CGI
CGI hypermethylation as determined by the COMPARE-MS
assay in differentiating primary prostate cancer from benign
prostate (Figure 7). Hypermethylation of all three of these
CGIs could achieve sensitivities >95% and speciﬁcities
Figure 6. COMPARE-MSappliedtoheterogeneousprostatetissues.(A–C)MIattheGSTP1,MDR1,PTGS2andESR1CGIsin20ngofgenomicDNAfrombenign
prostate tissues obtained from 13 organ donors, who had no evidence of prostatic malignancies (A), 20 ng of genomic DNA from tumor-adjacent benign prostate
cancertissuesisolatedfrom12ofthe130menfromwhomprostateswereobtainedduringradicalprostatectomyfortreatmentofprimaryprostatecancer(B)and20ng
ofgenomicDNAfromprimaryprostatecancertissuesfrom130primaryprostatecancerpatientsundergoingradicalprostatectomyfortreatmentoftheirdisease(C).
Asterisk denotes MI <0.2 but greater than the threshold determined by ROC curve analysis. These data demonstrate the applicability of COMPARE-MS to
heterogeneous human tissue samples.
e19 Nucleic Acids Research, 2006, Vol. 34, No. 3 PAGE 10 OF 14Figure 7. ComparisonofROCcurvesobtainedbyCOMPARE-MSwiththoseobtainedbyMethyLight.ROCcurvesforhypermethylationattheGSTP1,MDR1and
PTGS2CGIsindistinguishingbetweenbenignandmalignantprostateasdeterminedbyCOMPARE-MSwerecomparablewiththosegeneratedbyMethyLight(33).
AnidealassaywouldperfectlydistinguishbetweentruepositivesandtruenegativesandwouldhaveanareaundertheROCcurveof1.0.Thedashedlinesrepresent
the ROC curve for a hypothetical test that cannot distinguish between these two groups, giving an AUC of 0.5. CGI hypermethylation at the GSTP1, MDR1 and
PTGS2genesasdeterminedbyCOMPARE-MSdistinguishbenignprostatefromprostatecancerwithhighsensitivityandspecificity,withAUCsextremelycloseto
the ideal case.
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for these CGIs as determined by COMPARE-MS approached
1.0 and were comparable with those determined by MethyL-
ight (33). Interestingly, four out of the ﬁve prostate cancer
cases that had undetectable GSTP1 CGI hypermethylation by
MethyLight were found to be hypermethylated by the
COMPARE-MS assay. Furthermore, the one prostate cancer
case that had undetectable GSPT1 CGI hypermethylation by
the COMPARE-MS assay was also undetectable by MethyL-
ight. Taken together, these data demonstrate the applicability
of the COMPARE-MS assay for the sensitive, speciﬁc
and rapid identiﬁcation of aberrant CGI hypermethylation
in heterogeneous tissues.
DISCUSSION
This report describes a novel DNA methylation assay called
COMPARE-MS that greatly enriches for methylated DNA in
heterogeneous samples by combining two independent and
complementary strategies: (i) digestion with methylation-
sensitive restriction enzymes and (ii) speciﬁc capture of
methylated DNA by binding to MBD polypeptides immobil-
ized on a magnetic solid matrix. The enriched methylated
DNA is then subjected to gene-speciﬁc quantitative PCR to
determine quantities of methylated CGIs in DNA from het-
erogeneous samples. One signiﬁcant advantage of
COMPARE-MS over previous methods is that it does not
require sodium bisulﬁte modiﬁcation. For the methylation-
sensitive restriction enzyme step of COMPARE-MS, we
chose to use HpaII because its recognition site is abundant
in most CGIs. Other methylation-sensitive restriction enzymes
may be equally effective. The second step of COMPARE-MS,
capture and enrichment of methylated DNA fragments, is
similar to the previously reported MIRA (26), MeDIP (32)
and MECP2-MBD column(23–25)based assays. In particular,
the methylated-DNA capture step of COMPARE-MS is sim-
ilar to the MIRA assay, which uses full-length GST-tagged-
MBD2-bound magnetic beads for afﬁnity puriﬁcation of
methylated DNA fragments. However, one notable difference
between the methylated-DNA capture step of COMPARE-MS
and these previous techniques is that we used the small,
 10 kDa MBD fragment of MBD2 for afﬁnity capture and
enrichment of methylated DNA fragments, while the
MIRA, MeDIP and MECP2-MBD column-based assays
used full-length MBD2, a5mC-Abs or the MBD fragment
of MECP2, respectively. The use of MBD2-MBD in
COMPARE-MS may provide signiﬁcant advantages over
these other reagents for the capture and enrichment of methyl-
ated DNA. First, we show that the MBD2-MBD has high
afﬁnity and speciﬁcity for symmetrically methylated DNA
templates. Previous studies have also shown that of all the
MBD proteins, MBD2 has the highest afﬁnity for a wide range
of methylated DNA sequences (37), while MECP2may select-
ively bind to CpG dinucleotides adjacent to A/T-rich
sequences (38). Second, because it binds double-stranded
methylated DNA, MBD2-MBD may be a better candidate
for enrichment of CGIs than the a5mC-Abs which only
bindsingle-strandedDNA (32).This isanespeciallyimportant
consideration since the high G/C content of CGIs may make
these sequences resistant to denaturing and prone to forming
secondary structures even after denaturing. Finally, using just
the small  10 kDa MBD portion of the MBD2 protein, as
opposed to the full-length protein, could eliminate unwanted
interactions between unmethylated DNA and other domains
on the MBD2 protein. In this study, enrichment of methylated
DNA by the combination of digestion with HpaII and capture
with the MBD2-MBD minimized the rate of false positives,
while maintaining exquisite sensitivity. Furthermore, these
processes involve minimal ‘hands-on’ time and small reaction
volumes, making COMPARE-MS highly compatible with
automated, high-throughput, micro-titer plate analysis. After
the initial assay development and optimization stages, we
determined the methylation pattern of >160 prostate tissue
and cell line samples at multiple CGIs in a single day.
This analysis showed that the CGI hypermethylation pattern
at GSTP1, PTGS2 and MDR1 could identify prostate cancer
with sensitivities >95% and speciﬁcities approaching 100%.
Furthermore, we showed that the sensitivity, speciﬁcity and
dynamic range achieved by COMPARE-MS are highly
comparable with those reported for MSP, MethyLight and
HeavyMethyl. However, unlike these other techniques,
COMPARE-MS is not encumbered with the disadvantages
of sodium bisulﬁte modiﬁcation. This may allow for higher
compatibility with high-throughput, automated, micro-titre-
based platforms, and greater ease in the design of real-time
PCR primers since there is no reduction in genome sequence
complexity. Also, typically, MSP and MethyLight identify the
prevalence of a single pattern of methylationat the CpG dinuc-
leotides interrogated by the primers and probes. Although
theoretically it may be possible to carry out multiple reactions,
each interrogating a different pattern and different set of
CpGs, the low sequence complexity of bisulﬁte-treated
DNA limits the application of such strategies. COMPARE-
MS, on the other hand, was designed to detect a broader
range of abnormal methylation patterns across a large set of
CpG dinucleotides without signiﬁcant design limitations. This
feature of COMPARE-MS can be viewed as both a strength
and a weakness.
On the one hand, this difference between COMPARE-MS
versus MSP and MethyLight may be the reason that four out of
the ﬁve primary prostate cancer cases in which MethyLight
could not detect any GSTP1 CGI hypermethylation were
detected by the COMPARE-MS assay. More provocatively,
a larger fraction of the tumor-adjacent benign prostate tissues
had a small, but signiﬁcant, amount of methylated CGIs at the
GSTP1, PTGS2 and MDR1 genes when analyzed by
COMPARE-MS than when analyzed by MethyLight. This
ﬁnding is in agreement with a recent study showing that the
normal epithelia and stroma in tumor-adjacent benign tissues
in breast cancers displayed signiﬁcant hypermethylation of
CpG islands (39). Most of the tumor-adjacent benign tissues
in this study had some prostatic intraepithelial neoplasia (PIN)
and/or proliferative inﬂammatory atrophy lesions, which have
been shown to have some methylation at the GSTP1 CGI by
MSP, but only after rigorous puriﬁcation of these cells by laser
capture microdissection (LCM) (34). In this study, even with-
out LCM, we were able to quantitatively detect trace amounts
of hypermethylation at these CGIs by COMPARE-MS,
illustrating theutilityofthistechniqueinhighlyheterogeneous
tissues containing only a small amount of methylated DNA.
However, since LCM was not used, we could not rule out the
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trace contamination by cancer cells. Larger studies, using
LCM in at least a subset of samples, would have to be
performed to verify this ﬁnding.
On the other hand, the ability to detect a broader range of
methylation patterns is also a limitation of COMPARE-MS,
because it would not be able to quantitate the prevalence of
speciﬁc patterns of CpG dinucleotide methylation in a given
sample. The role of COMPARE-MS would therefore be to
quantitate the degree of aberrant hypermethylation with high
sensitivity, speciﬁcity and rapidity. If necessary, speciﬁc sam-
ples of interest, as identiﬁed by COMPARE-MS, can then be
studied by the use of other techniques such as bisulﬁte
genomic sequencing (36) for determination of the prevalence
of speciﬁc patterns of DNA methylation.
The COMPARE-MS assay, or components of it, may
also be useful for many different methylation detection
applications that were not explored in this study. First of
all, its sensitivity, speciﬁcity and ease of use would allow
for design of large clinical trials testing the efﬁcacy of
DNA methylation patterns in the diagnosis and risk stratiﬁca-
tion of human diseases, including cancer. Additionally, since
COMPARE-MS does not involve bisulﬁte modiﬁcation of the
DNA, the original DNA sequence complexity is preserved.
Consequently, multiplexing methylation detection at several
CGIs in a single assay may be possible. Also, COMPARE-MS
may be modiﬁed slightly to allow unbiased detection of novel
methylated regions by a number of strategies including
microarray hybridization (32,40,41), digital karyotyping
(39), restriction fragment length genome scanning (42), etc.
The use of COMPARE-MS could not only enhance our under-
standing of the role of DNA methylation in health and disease,
but improve our ability to sensitively, speciﬁcally and rapidly
detect CGI hypermethylation.
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